Evidence map›Paper›PMID 24918453›Full record

ReviewMarine drugs2014

Emerging strategies and integrated systems microbiology technologies for biodiscovery of marine bioactive compounds.

Javier Rocha-Martin, Catriona Harrington, Alan D W Dobson, Fergal O'Gara

Abstract readReview
In one paragraph

Review in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Microbial genomics · 2021
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Javier Rocha-MartinBIOMERIT Research Centre, School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland. jrocha@ucc.ie.
Catriona HarringtonBIOMERIT Research Centre, School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland. catriona.harrington@ucc.ie.
Alan D W DobsonSchool of Microbiology, University College Cork, National University of Ireland, Cork, Ireland. a.dobson@ucc.ie.
Fergal O'GaraBIOMERIT Research Centre, School of Microbiology, University College Cork, National University of Ireland, Cork, Ireland. f.ogara@ucc.ie.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marine microorganisms continue to be a source of structurally and biologically novel compounds with potential use in the biotechnology industry. The unique physiochemical properties of the marine environment (such as pH, pressure, temperature, osmolarity) and uncommon functional groups (such as isonitrile, dichloroimine, isocyanate, and halogenated functional groups) are frequently found in marine metabolites. These facts have resulted in the production of bioactive substances with different properties than those found in terrestrial habitats. In fact, the marine environment contains a relatively untapped reservoir of bioactivity. Recent advances in genomics, metagenomics, proteomics, combinatorial biosynthesis, synthetic biology, screening methods, expression systems, bioinformatics, and the ever increasing availability of sequenced genomes provides us with more opportunities than ever in the discovery of novel bioactive compounds and biocatalysts. The combination of these advanced techniques with traditional techniques, together with the use of dereplication strategies to eliminate known compounds, provides a powerful tool in the discovery of novel marine bioactive compounds. This review outlines and discusses the emerging strategies for the biodiscovery of these bioactive compounds.

Indexed as

AnimalsBiocatalysisBiological ProductsBiotechnologyDrug DiscoveryHumansMarine BiologyBiological Products

Identifiers

PMID24918453
PMCPMC4071589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.